ClinicalTrials.gg
Status unknownNCT03608007Updated Jan 9, 2020

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

A Phase 2 interventional study of X-396 Capsule in Lung Cancer and ROS1 Gene Rearrangement, sponsored by Betta Pharmaceuticals Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-09.

Sponsored by Betta Pharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 844 studies in Lung Neoplasms with a site in China — 371 open to participants now, 418 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
328th of 585
69 · median 90
Started
2018
with 58 others
Phase 2
151 of 844
73 open now
Registered
213th of 844
by date

Among the 844 studies in Lung Neoplasms with a site in China, this one is the 328th largest by planned enrollment of the 585 interventional ones that give a count, is one of 59 that started in 2018, is one of 151 in phase 2, and was the 213th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

371 of the 844 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

366 more — sign in →

All 371 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 844 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

To assess treatment effectiveness and safety of oral X-396 capsule (Ensartinib) administered to Chinese patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a c-ROS Oncogene (ROS1) positive gene mutation (translocation or inversion).

Read the detailed description

This is a phase II, multicenter, single-arm study in which the efficacy and safety of X-396 capsule (Ensartinib) will be assessed in adult Chinese patients with ROS1-positive (rearrangement or inversion) non-small cell lung cancer (NSCLC). Approximately 69 patients (59 for never-treated, and 10 for previously treated with crizotinib) with locally advanced or metastatic NSCLC carrying ROS1-rearrangement will be enrolled in the study.

03

Conditions studied

  • Lung Cancer
  • ROS1 Gene Rearrangement

Browse trials for

Keywords

  • ROS1 NSCLC
  • X-396
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male, 18 years of age or older
  • or cytologically proven diagnosis of NSCLC that is locally advanced or
  • Positive for translocation or inversion events involving the ROS1 gene
  • Tyrosine kinase inhibitor (TKI) treatment-naive or have previously received no more than one systemic treatment regimen(s) such as chemotherapy (After a 3-week )
  • (ECOG) performance status 0 to 1
  • Predicted survival ≥ 3 months
  • Drug related toxicities were relieved to grade 1, except for hair loss (based on v4.03)
  • Adequate organ function
  • At least 1 measurable tumor lesion as per v1.1
  • Asymptomatic central nervous system (CNS) metastases do not require the use of or anticonvulsants.
  • Signed and dated
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
  • Agree to use effective during the study period and for at least 90 days after completion of the study treatment

Exclusion criteria

Exclusion Criteria:

  • Current treatment on another systemic anti-cancer therapy
  • Prior therapy specifically directed against ROS1 fusion genes (except for the exploratory arm that will enroll patients pretreated with crizotinib)
  • Evidence of active within last 3 years
  • Previous therapeutic clinical trial must have completed at least 4 week prior to initiation of study drug
  • Prior surgery or immunotherapy must have completed at least 4 weeks, and radiation must have been completed at least 2 weeks prior to initiation of study drug
  • Known interstitial fibrosis or interstitial lung disease
  • Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medication
  • cardiovascular disease
  • Patients with a known allergy or delayed reaction to study drug or its
  • Pregnant or breast feeding
  • Use of drugs or foods that are known potent inhibitors or inducers
  • Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol
  • Other serious illness or medical condition potentially interfering with the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (estimated)

Study arms

  • Experimental
    X-396 Capsule

    Single-arm trial whereby all consented, enrolled, eligible patients receive X-396 capsule, 225 mg once daily.

    Drug: X-396 Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) based on independent radiology review (IRC) according to RECIST 1.1

    ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR), based on IRC.

    Time frame: 12 weeks

Secondary outcomes

  1. ORR based on investigator assessment according to RECIST 1.1

    ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as CR or PR, based on investigator's assessment

    Time frame: 12 weeks

  2. Disease control rate (DCR) according to RECIST 1.1

    DCR defined as the percentage of patients who have achieved CR, PR and stable disease (SD), based on RECIST 1.1 measured by IRC or investigator

    Time frame: 12 weeks

  3. Intracranial overall response rate (iORR) by IRC and investigator assessment according to RECIST 1.1

    iORR calculated as the ORR (CR+PR) of lesions in the brain for patients who have measurable disease in the brain at baseline.

    Time frame: 12 weeks

  4. Progression-free survival (PFS) based on IRC or investigator according to RECIST 1.1

    PFS defined as time from first dose of X-396 capsule to disease progression or death due to any cause, based on RECIST 1.1.

    Time frame: 36 months

  5. Time to progression (TTP) based on IRC or investigator according to RECIST 1.1

    TTP defined as time from first dose of X-396 capsule to disease progression, based on RECIST 1.1.

    Time frame: 36 months

  6. Duration of response (DOR) based on IRC or investigator according to RECIST 1.1

    DOR defined as time from documentation of tumor response (CR or PR) to disease progression or death, based on RECIST 1.1

    Time frame: 36 months

  7. Overall survival (OS)

    OS, defined as time from first dose of X-396 to death due to any cause.

    Time frame: 36 months

  8. Change From Baseline Scores on the functional assessment of cancer therapy - Lung (FACT-L) quality of life questionnaire

    The FACT-L questionnaire consisted of several major aspects of life (Physical, social/family, emotional, and functional well-being) as well as lung cancer subscale (symptoms, cognitive function, regret of smoking). Scores for item ranging from 0 (not at all) to 4 (very much).

    Time frame: 36 months

  9. Incidence of patients experiencing adverse events (AE)

    Adverse events are graded according to CTCAE 4.03

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
  • Chest hospital affiliated to Shanghai jiao tong university
    Shanghai, Shanghai 200000, China
    Recruiting
    • Shun Lu · Contact
    • Shun Lu, Ph.D · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2018 (actual). Primary completion is estimated for Mar 2020, 21 months after the start.

Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 21 months is below that.

Counting every sponsor, half of 364 studies reached it within 65 months; a quarter within 34 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2018
First posted
Jul 31, 2018
StartActual
Jun 15, 2018
Primary completionEst.
Mar 2020
CompletionEst.
Sep 2020
Last update
Jan 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03608007
Responsible party
Sponsor
First posted
Jul 31, 2018
Start date
Jun 15, 2018
Primary completion
Mar 2020 (estimated)
Completion
Sep 2020 (estimated)
Last update
Jan 9, 2020

Study contacts

Jinxiao Xu
Contact
jinxiao.xu@bettapharma.com
86-18610155290
Shun Lu
principal investigator · PHD

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensartinib

Start the discussion